-
公开(公告)号：US20170188555A1
公开(公告)日：2017-07-06
申请号：US15348306
申请日：2016-11-10
Applicant: Omeros Corporation
Inventor： George A. Gaitanaris , John E. Bergmann , Alexander Gragerov , John Hohmann , Fusheng Li , Linda Madisen , Kellie L. McIlwain , Maria N. Pavlova , Demetri Vassilatis , Hongkui Zeng
IPC: A01K67/027 , A61K49/00 , C07K14/72 , G01N33/50
CPC classification number: A01K67/0278 , A01K2217/00 , A01K2217/052 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K49/0008 , C07K14/723 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/5023 , G01N2333/726 , G01N2800/04 , G01N2800/28 , G01N2800/50
Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.
-
公开(公告)号：US20230110784A1
公开(公告)日：2023-04-13
申请号：US17823793
申请日：2022-08-31
Applicant: Omeros Corporation
Inventor： Gregory A. Demopulos , George A. Gaitanaris , Roberto Ciccocioppo
IPC: A61K31/551 , A61K31/5513 , A61K31/5377 , A61K31/53 , A61K31/4985 , A61K31/496 , A61K31/519 , A61K31/527 , A61K31/46 , A61K31/435 , A61K31/4439 , A61K31/433 , A61K31/4178 , A61K31/4162 , A61K31/4025 , A61K31/35 , A61K45/06 , A61K31/135 , A61K31/137 , A61K31/197 , A61K31/337 , A61K31/357 , A61K31/381 , A61K31/385 , A61K31/4015 , A61K31/44 , A61K31/454 , A61K31/485 , A61K31/505 , A61K31/517 , A61K31/55 , A61K31/465
Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
-
公开(公告)号：US10292374B2
公开(公告)日：2019-05-21
申请号：US15348306
申请日：2016-11-10
Applicant: Omeros Corporation
Inventor： George A. Gaitanaris , John E. Bergmann , Alexander Gragerov , John Hohmann , Fusheng Li , Linda Madisen , Kellie L. McIlwain , Maria N. Pavlova , Demetri Vassilatis , Hongkui Zeng
IPC: A01K67/027 , C07K14/72 , C12Q1/6883 , A61K49/00 , G01N33/50 , A61K38/00
Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.
-
公开(公告)号：US20160015715A1
公开(公告)日：2016-01-21
申请号：US14806007
申请日：2015-07-22
Applicant: Omeros Corporation
Inventor： John E. Bergmann , Neil S. Cutshall , Gregory A. Demopulos , Vincent A. Florio , George A. Gaitanaris , Patrick Gray , John Hohmann , Rene Onrust , Hongkui Zeng
IPC: A61K31/551 , A61K31/4162 , A61K31/506 , A61K31/505 , A61K31/4025 , A61K31/381 , A61K31/4985 , A61K31/122 , A61K31/085 , A61K31/192 , A61K31/527 , A61K31/542 , A61K45/06 , A61K31/198 , A61K31/4439
CPC classification number: A61K31/551 , A61K31/00 , A61K31/085 , A61K31/122 , A61K31/137 , A61K31/192 , A61K31/195 , A61K31/198 , A61K31/381 , A61K31/4025 , A61K31/4162 , A61K31/425 , A61K31/433 , A61K31/4439 , A61K31/4985 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/527 , A61K31/542 , A61K45/06 , C07D471/04 , A61K2300/00
Abstract: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.
Abstract translation: 通过施用治疗有效量的PDE7抑制剂来治疗与神经运动障碍的病理学相关的运动异常的方法，例如帕金森病或不宁腿综合症。 本发明的一个方面提供了与多巴胺激动剂或前体如左旋多巴结合施用PDE和抑制剂。 在本发明的另一方面，PDE7抑制剂可以相对于已知与帕金森病病理学有关的其它分子靶标（i）可能对PDE7具有选择性，或（ii）其他治疗有效的药物 治疗帕金森病。
-
5.发明授权公开(公告)号：US09220715B2
公开(公告)日：2015-12-29
申请号：US13835607
申请日：2013-03-15
Applicant: Omeros Corporation
Inventor： Gregory A. Demopulos , George A. Gaitanaris , Roberto Ciccocioppo
IPC: A61K31/5513 , A61K31/5377 , A61K31/53 , A61K31/4985 , A61K31/496 , A61K31/519 , A61K31/527 , A61K31/46 , A61K31/435 , A61K31/4439 , A61K31/433 , A61K31/4178 , A61K31/4162 , A61K31/4025 , A61K31/35 , A61K45/06 , A61K31/135 , A61K31/137 , A61K31/197 , A61K31/337 , A61K31/357 , A61K31/381 , A61K31/385 , A61K31/4015 , A61K31/44 , A61K31/454 , A61K31/485 , A61K31/505 , A61K31/517 , A61K31/55
CPC classification number: A61K31/551 , A61K31/135 , A61K31/137 , A61K31/197 , A61K31/337 , A61K31/35 , A61K31/357 , A61K31/381 , A61K31/385 , A61K31/4015 , A61K31/4025 , A61K31/4162 , A61K31/4178 , A61K31/433 , A61K31/435 , A61K31/44 , A61K31/4439 , A61K31/454 , A61K31/46 , A61K31/465 , A61K31/485 , A61K31/496 , A61K31/4985 , A61K31/505 , A61K31/517 , A61K31/519 , A61K31/527 , A61K31/53 , A61K31/5377 , A61K31/55 , A61K31/5513 , A61K45/06 , A61K2300/00
Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Abstract translation: 本公开涉及使用磷酸二酯酶7（PDE7）抑制剂单独或与其它治疗剂组合治疗成瘾和初次冲动控制障碍。
-
Patent Agency Ranking
公开(公告)号：US20240307537A1
公开(公告)日：2024-09-19
申请号：US18451632
申请日：2023-08-17
Applicant: Omeros Corporation
Inventor： Michael Cicirelli , Neil S. Cutshall , Gregory A. Demopulos , George A. Gaitanaris , Marc A. Gavin , Alexander Gragerov , Thomas L. Little , Rene Onrust
IPC: A61K39/00 , A61K31/17 , A61K31/341 , A61K31/381 , A61K31/4409 , A61K31/473 , A61K31/495 , A61K31/496 , A61K31/502 , A61K31/506 , A61K31/519 , A61K31/522 , A61K31/53 , A61K31/55 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/28 , G01N33/574
CPC classification number: A61K39/4643 , A61K31/17 , A61K31/341 , A61K31/381 , A61K31/4409 , A61K31/473 , A61K31/495 , A61K31/496 , A61K31/502 , A61K31/506 , A61K31/519 , A61K31/522 , A61K31/53 , A61K31/55 , A61K39/39558 , A61K45/06 , A61P35/00 , C07K16/28 , G01N33/57488 , A61K2039/505 , A61K2039/545 , C07K2317/76
Abstract: This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).
-
公开(公告)号：US11464785B2
公开(公告)日：2022-10-11
申请号：US16191119
申请日：2018-11-14
Applicant: Omeros Corporation
Inventor： Gregory A. Demopulos , George A. Gaitanaris , Roberto Ciccocioppo
IPC: A61K31/4162 , A61K31/4439 , A61K31/505 , A61K31/44 , A61K31/4015 , A61K31/381 , A61K31/551 , A61K31/5513 , A61K31/135 , A61K31/4025 , A61K31/4178 , A61K31/519 , A61K31/4985 , A61K31/35 , A61K31/433 , A61K31/435 , A61K31/46 , A61K31/527 , A61K31/496 , A61K31/53 , A61K31/5377 , A61K31/465 , A61K31/55 , A61K31/517 , A61K31/485 , A61K31/454 , A61K31/385 , A61K31/357 , A61K31/337 , A61K31/197 , A61K31/137 , A61K45/06
Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
-
公开(公告)号：US11207275B2
公开(公告)日：2021-12-28
申请号：US15871768
申请日：2018-01-15
Applicant: Omeros Corporation
Inventor： Gregory A. Demopulos , George A. Gaitanaris
IPC: A61K31/00 , A61K31/135 , A61K31/137 , A61K31/197 , A61K31/381 , A61K31/454 , A61K31/485 , A61K31/4985 , A61K31/517 , A61K31/519 , A61K31/337 , A61K31/357 , A61K31/385 , A61K31/4015 , A61K31/4025 , A61K31/4178 , A61K31/44 , A61K31/505 , A61K31/55
Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
-
公开(公告)号：US20190134055A1
公开(公告)日：2019-05-09
申请号：US16191119
申请日：2018-11-14
Applicant: Omeros Corporation
Inventor： Gregory A. Demopulos , George A. Gaitanaris , Roberto Ciccocioppo
IPC: A61K31/551 , A61K31/5513 , A61K31/135 , A61K31/4025 , A61K31/4178 , A61K31/519 , A61K31/4985 , A61K31/35 , A61K31/4162 , A61K31/433 , A61K31/4439 , A61K31/435 , A61K31/46 , A61K31/527 , A61K31/496 , A61K31/53 , A61K31/5377 , A61K31/465 , A61K31/55 , A61K31/517 , A61K31/505 , A61K31/485 , A61K31/454 , A61K31/44 , A61K31/4015 , A61K31/385 , A61K31/381 , A61K31/357 , A61K31/337 , A61K31/197 , A61K31/137 , A61K45/06
Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
-
公开(公告)号：US20160282365A1
公开(公告)日：2016-09-29
申请号：US15007805
申请日：2016-01-27
Applicant: Omeros Corporation
Inventor： George A. Gaitanaris , John E. Bergmann , Alexander Gragerov , John Hohmann , Fusheng Li , Linda Madisen , Kellie L. McIlwain , Maria N. Pavlova , Demetri Vassilatis , Hongkui Zeng
IPC: G01N33/74
CPC classification number: G01N33/74 , A61K38/00 , C07K14/705 , C07K14/723 , C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N2333/726 , G01N2500/04 , G01N2500/10 , Y02A50/463 , Y02A50/469 , Y02A50/475 , Y02A50/48
Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.05 seconds)
